Eli Lilly ($LLY) completed its acquisition of AtaiBeckley ($ATAI) on September 11, 2026, paying $6.75 per share in cash plus one contingent value right (CVR) worth up to $2.50 more if specific drug-development milestones are reached. For former AtaiBeckley holders, the open question is no longer the stock price but whether those milestone payments ever arrive. This piece updates our July 16 coverage, which was written as reports of talks first broke, and corrects the share-price move we reported then.

What happened

On Thursday, July 16, 2026, Bloomberg News reported that Lilly was in talks to acquire AtaiBeckley, citing people familiar with the matter. The same day, the two companies announced a definitive agreement. According to AtaiBeckley's joint press release filed with the SEC, Lilly agreed to buy all outstanding shares for $6.75 in cash at closing plus a CVR of up to $2.50 per share. The merger agreement itself is dated July 15, 2026.

AtaiBeckley is a clinical-stage company developing what it calls rapid-acting neuroplastogens. Its lead program, BPL-003 (mebufotenin benzoate), is a synthetic form of 5-MeO-DMT given as a nasal spray for treatment-resistant depression. The release states that BPL-003 holds FDA Breakthrough Therapy Designation and "has initiated Phase 3 activities." The second program, VLS-01, is a DMT buccal film in an ongoing Phase 2b study. Carole Ho, president of Lilly Neuroscience, said advancing AtaiBeckley's therapies "gives us a real chance to change that," referring to patients whose depression persists after multiple treatments have failed.

The numbers

The deal terms below come from the July 16 release and AtaiBeckley's closing 8-K of September 11. Share prices are daily closes according to Financial Modeling Prep market data.

Measured against the last close before the news, the cash price was a premium of about 25.9% ($6.75 / $5.36 = 1.259). The roughly 40% figure the companies cite uses a 30-day average price instead, which explains the gap.

The more instructive number is what the market paid above the cash. At the July 16 close of $7.15, investors were implicitly valuing the CVR at about $0.40 per share ($7.15 minus $6.75). By the final close of $7.35, that implied value had risen to about $0.60 ($7.35 minus $6.75), or roughly 24% of the $2.50 maximum ($0.60 / $2.50). That is a rough reading, since it ignores the time value of money before closing and the small chance the deal would fail, but it shows that the market priced the milestones as possible, not probable.

Correcting the record on the 66% move

Our original headline said AtaiBeckley shares surged 66%. We cannot verify that figure. According to Financial Modeling Prep, the stock closed at $5.36 on July 15 and $7.15 on July 16, a regular-session gain of 33.4% ($7.15 / $5.36 = 1.334). Early reports that morning, such as an InvestorsHub article carried on Finviz, said the shares jumped as much as 53% in premarket trading. A 66% gain from $5.36 would mean a price near $8.90 ($5.36 x 1.66), while Financial Modeling Prep lists the stock's 52-week high at $7.45. We have replaced the 66% figure with the verified closing move.

The data also show a 14.1% rise on July 14 ($4.97 to $5.67), two days before the announcement, followed by a 5.5% decline on July 15. We note the move without drawing conclusions about its cause.

What has happened since

The deal moved through its conditions on schedule, according to AtaiBeckley's SEC filings:

• Regulatory clearance: the U.S. Hart-Scott-Rodino waiting period expired at 11:59 p.m. Eastern Time on August 28, 2026, per an August 31 filing.
• Shareholder vote: at a special meeting on September 8, holders cast 237,762,253 votes for the merger and 5,033,755 against, with 555,549 abstentions, per a September 8 filing. The votes in favor equal about 64.1% of the 370,864,669 shares outstanding on the record date (237,762,253 / 370,864,669). Holders of about 15% of the stock had signed voting agreements in July.
• Closing: the merger closed on September 11, 2026, and AtaiBeckley became a wholly owned Lilly subsidiary. Its directors resigned, and the company asked Nasdaq to suspend trading and file to delist the shares. Lilly announced completion the same day in a press release.

Through July and August, several plaintiff law firms issued press releases announcing investigations into the price and process of the sale. Those releases are solicitations, not findings, and the shareholder vote passed by a wide margin.

Lilly stock barely registered the deal. It rose 1.08% on announcement day ($1,156.63 to $1,169.17) and traded at $1,261.51 at midday on October 16, up 7.90% from the July 16 close, according to Financial Modeling Prep.

What it means for shareholders

Former AtaiBeckley holders received $6.75 in cash per share and now hold a CVR that, according to the closing 8-K, is not transferable except in limited circumstances, will not be listed on any exchange, and carries no voting or dividend rights. In practice, it is a long-dated claim that cannot be sold. Its value depends on development decisions Lilly now controls, and the release states plainly that "there can be no assurance that any payments will be made." Anyone who bought shares at the final $7.35 close needs at least $0.60 per share from the CVR just to break even on that purchase.

Lilly holders should see this as a small, measured bet. The $2.8 billion upfront value is about 0.24% of Lilly's roughly $1.19 trillion market capitalization as reported by Financial Modeling Prep ($2.8 billion / $1,187.7 billion), and even the full $3.8 billion would be about 0.32%. About 26% of the potential price ($1.0 billion / $3.8 billion) is payable only if the programs succeed. Paying for results rather than promises is the kind of capital discipline conservative investors should want from a company of Lilly's size. For more on how we weigh deals like this, see our Analysis section.

Risks and what to watch

• CVR deadlines: counting from the September 11, 2026 closing, the VLS-01 Phase 3 milestone must be met before September 11, 2030; the BPL-003 approval milestone before September 11, 2031; and the VLS-01 approval milestone before September 11, 2033.
• Two regulators, not one: each approval milestone requires both U.S. regulatory approval and DEA rescheduling. A drug that clears the FDA but waits on rescheduling would not trigger payment.
• Clinical risk: BPL-003 has started Phase 3 activities and VLS-01 is in Phase 2b. Neither has completed late-stage trials, and a failed or delayed trial would push back or eliminate the related payments.
• Lilly's disclosures: the release said Lilly would determine accounting treatment at closing and reflect the deal in its financial results and guidance. Watch upcoming Lilly reports for updates on the BPL-003 Phase 3 program.

The bottom line: the takeover is finished, the cash has been paid, and what remains is an option on a new class of depression treatment. Former holders should value the CVR conservatively. Follow our continuing coverage of U.S. and Canadian markets at Wall Street Conservative.

Updated October 16, 2026: expanded and updated with developments since publication.